KalVista Reports Strong Preliminary EKTERLY Revenue and Rapid Patient Adoption Post-Launch

summarizeSummary

KalVista Pharmaceuticals announced strong preliminary global net product revenue of $49 million for its EKTERLY launch, demonstrating rapid patient adoption and significant commercial momentum for its HAE treatment.

check_boxKey Events

• Strong Preliminary Revenue Reported

  KalVista announced preliminary unaudited global net product revenue of approximately $49 million for EKTERLY for the eight-month transition period ended December 31, 2025, including $35 million for the fourth quarter.

• Rapid US Patient Adoption

  The company recorded 1,318 patient start forms and activated 580 unique prescribers in the US through December 31, 2025, reflecting rapid adoption of EKTERLY.

• Refills Surpass Initial Prescriptions

  In Q4 2025, prescription refills for EKTERLY surpassed initial prescriptions as the primary driver of revenue, indicating strong patient satisfaction and continued use.

• Global Commercial Expansion

  EKTERLY is demonstrating strong early adoption in Germany, and KalVista has partnered with Multicare Pharma to commercialize sebetralstat in Latin America.

auto_awesomeAnalysis

KalVista Pharmaceuticals has reported highly encouraging preliminary revenue figures for its recently launched HAE treatment, EKTERLY. The $49 million in global net product revenue for the eight-month period, including $35 million in Q4 2025, indicates a robust commercial uptake for a new product. The strong patient adoption metrics, with over 1,300 patient start forms and refills surpassing initial prescriptions, suggest growing market acceptance and physician confidence. This positive momentum, coupled with international expansion and a planned pediatric NDA filing, provides a clear growth trajectory for the company. While the financials are preliminary and unaudited, the operational indicators strongly support the commercial success of EKTERLY, which is reflected in the stock trading near its 52-week high.